Business Context and Reporting Period
This Form 8-K filing by Seres Therapeutics, Inc. (a Delaware corporation and emerging growth company) reports a corporate governance event dated April 18, 2019. The filing addresses the appointment of a senior executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
On April 18, 2019, the Board of Directors appointed Marcus Chapman as the Company's Principal Financial and Accounting Officer. Mr. Chapman continues in his existing role as Vice President, Finance, a position he has held since January 2018. Prior to joining Seres, Mr. Chapman served in senior finance roles at Takeda Oncology, Clarion Healthcare Consulting, Strategic Decisions Group, and LaSalle Partners.
Compensation and Equity Grants
As part of his appointment and continued service, the filing details the following equity holdings and grants for Mr. Chapman:
- Stock Options:
- 25,000 shares granted March 25, 2015 ($15.77 exercise price).
- 12,500 shares granted February 1, 2016 ($26.20 exercise price).
- 10,000 shares granted January 26, 2017 ($9.89 exercise price).
- 18,000 shares granted January 30, 2018 ($10.42 exercise price).
- 23,000 shares granted February 1, 2019 ($6.38 exercise price).
- 23,000 shares granted February 6, 2019 ($6.15 exercise price; subject to performance-based vesting).
- Vesting Schedule: Options (i) through (v) vest 25% on the first anniversary of the grant date, followed by quarterly installments over three years. Option (vi) is performance-based.
- Restricted Stock Units (RSUs):
- 7,500 RSUs granted December 7, 2016 (fully vested and sold).
- 12,000 RSUs granted November 26, 2018 (vest in full on November 1, 2019).
Investor Verification Checklist
- Verify the current market price of Seres Therapeutics common stock relative to the exercise prices of Mr. Chapman's outstanding options.
- Confirm the specific performance metrics required for the vesting of the 23,000 options granted on February 6, 2019.
- Review the Company's most recent 10-Q or 10-K for updated financial position and cash runway, as this 8-K contains no financial data.
- Monitor future filings for any changes to the vesting schedule of the 12,000 RSUs due November 1, 2019.